Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 319181

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 319181

License Grant
Licensor grants to the Licensee (of Israel) an exclusive right and license throughout the Territory, with the right to grant sub licenses, to practice under the Licensor Intellectual Property to develop, make. have made, use. sell, have sold. offer for sale, import, export, register, market, promote and otherwise Commercialize the Compound and Products in the Field for all indications.
License Property
Licensor owns or Controls the Licensor Intellectual Property relating to Compound for the treatment of stuttering.

Compound means singly and collectively 2-(7-chloro-1, 8-naphtyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone, the (+) enantiomer of which is known as RP62955 or pagoclone.

Product means any pharmaceutical preparation in final form, or, where the context so indicates, the form under development, containing the Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional for use in the Territory.

Field of Use
Pagoclone enhances the activity in GABA circuits in the brain and thus may help restore more normal function in speech areas of the brain.

IPSCIO Record ID: 211892

License Grant
Licensor grants an exclusive right and license in the Field, with the right to grant sublicenses to Affiliates of Licensee and of Parent at the time of such grant, to practice under the Licensors Intellectual Property, solely to use, import, offer for sale, and Promote Product in the Territory;  and an exclusive, even as to Licensor, right and license in the Field, with the right to grant sublicenses to Affiliates of Licensee and of Parent at the time of such grant, to practice under the Licensors Intellectual Property, solely to sell and distribute Product in the Territory.
License Property
The licensed property relates to the chemical compound known as trospium chloride whose specific chemical name is 3-alpha-benziloyloxynortropane-8-spiro-1’-pyrrolidinium chloride, also known as spiro[8-azoniabicyclo[3,2,1]octane-8,1’-pyrrolidinium]-3-[(hydroxydiphenyl-acetyl)-oxy]chloride(1a, 3ß, 5a)-(9Cl) and any related analogues, homologues, derivative and other pharmaceutically active salts.

The Product means any pharmaceutical preparation in final form (or, where the context so indicates, the form under development) containing Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional, for use in the Territory.

The Finished Product means the oral dosage formulation of Trospium Twice-Daily described in the Specifications and packaged and labeled and in a form ready for distribution in the Territory.

Trospium chloride is used to treat overactive bladder.

Field of Use
The Field means any oral formulation of Product for any human pharmaceutical use, and any transdermal or intravesicle formulation of Product for ·use in the treatment of overactive bladder and/or urinary incontinence in any form.

IPSCIO Record ID: 372521

License Grant
Licensor grants to Licensee of Germany, an exclusive right and license under the Licensor Patent Rights, the Licensor Know-How and Licensors interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold PET Ligand and Products in the Field in the Territory.

Licensee has the right to develop and commercialize the PET Ligand as set forth.

License Property
Licensor has discovered proprietary compounds of the NMDA class and possesses proprietary intellectual property rights relating thereto, including the Licensor Patent Rights.

Licensor patents and technology relate to Imidazole Derivatives.  The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and  of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).

The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.

The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.

The term EVT 101 shall mean xO-4394127.

The term EVT 103 shall mean xO-0717626.

The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.

Field of Use
The patent portfolio covers NMDA receptor NR2B subtype selective antagonists (the
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.